UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• UBS Asset Management reduced its Zimmer Biomet stake by 0.9% in the second quarter, selling 12,667 shares and retaining 1.46 million shares worth approximately $125.5 million. Institutional investors collectively own 88.89% of the company.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 adjusted EPS and $2.18 billion in revenue, while revenue increased 4.8% year over year. The company maintained fiscal 2026 EPS guidance of $8.47–$8.59.
• The company declared a quarterly dividend of $0.24 per share, equivalent to a $0.96 annualized payout and a 1.0% yield. Analysts maintain a consensus “Hold” rating with an average price target of $104.42.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 0.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,457,553 shares of the medical equipment provider's stock after selling 12,667 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.76% of Zimmer Biomet worth $125,481,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. DV Equities LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $25,000. Tacita Capital Inc purchased a new stake in shares of Zimmer Biomet during the second quarter worth about $26,000. Ancora Advisors LLC bought a new stake in shares of Zimmer Biomet in the second quarter worth about $29,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet during the 4th quarter valued at about $30,000. Finally, Gen Wealth Partners Inc purchased a new position in Zimmer Biomet during the 4th quarter valued at about $31,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Down 0.5%

ZBH stock opened at $99.52 on Wednesday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $106.88. The business's 50 day moving average price is $94.38 and its two-hundred day moving average price is $91.55. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market capitalization of $18.98 billion, a price-to-earnings ratio of 24.21, a price-to-earnings-growth ratio of 1.89 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same quarter in the prior year, the company earned $2.07 EPS. The business's revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet's dividend payout ratio (DPR) is currently 23.36%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ZBH shares. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a report on Thursday, August 6th. Weiss Ratings raised Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday, August 4th. Truist Financial raised their price target on Zimmer Biomet from $92.00 to $106.00 and gave the stock a "hold" rating in a research note on Thursday, August 6th. BMO Capital Markets reiterated a "market perform" rating and issued a $96.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Finally, Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus price target of $104.42.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source